BioNTech SE

BioNTech SE engages in the development of novel medicines at the intersection of immunology and synthetic biology. Its product pipeline include BNT162b2, BNT161, BNT164, FixVac, iNeST, RiboMabs, CAR-T Cells, TCRs and Next-Gen CP Immunomodulators. The company was founded by Christopher Huber, Ozlem Tureci and Ugur Sahin on June 2, 2008 and is headquartered in Mainz, Germany.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

BioNTech reports robust 2022 earnings, eyes growth in oncology and infectious diseases

BioNTech's strong financial performance in 2022 sets the stage for continued growth in 2023, with a focus on expanding its vaccine portfolio, advancing oncology programs, and navigating the evolving landscape of COVID-19. The company's strategic priorities align with market demands for infectious disease and oncology solutions, positioning BioNTech for future success and profitability.

BioNTech posts robust Q1 results, eyes growth in vaccines and oncology

BioNTech's Q1 2023 performance reflects strong financial results and promising developments in its vaccine and oncology programs.
While facing challenges such as seasonal trends and data constraints, the company is strategically positioned to leverage opportunities in commercial planning and therapeutic advancements.
With a focus on synergistic partnerships and innovative technologies, BioNTech aims to maintain its competitive edge in the biopharmaceutical industry.
The company's commitment to enhancing existing platforms and exploring new growth avenues underscores its resilience and adaptability in a dynamic market environment.

BioNTech reports mixed Q2 results, focuses on innovation and growth

BioNTech's Q2 2023 performance reflects a mix of strong revenue generation and financial challenges, emphasizing the importance of strategic focus.
The company's strengths lie in its innovative collaborations, pipeline advancements, and preparedness for market demands, despite facing financial losses.
Navigating challenges in financial sustainability, market competition, and stakeholder communication will be crucial for BioNTech's future growth and success.

BioNTech adjusts revenue guidance amidst vaccine demand challenges

BioNTech's Q3 2023 performance reflected revenue challenges from lower COVID-19 vaccine demand and write-downs, prompting revised revenue guidance.
Despite challenges, the company showcased strengths in vaccine development, oncology advancements, and strategic cost management initiatives.
Opportunities lie in shared R&D expenses, long-term growth prospects from combination vaccines, and maintaining financial strength during market transition.

BioNTech reports strong Q4 earnings, eyes diversified product expansion

BioNTech is strategically investing in expanding its product portfolio while navigating uncertainties in COVID-19 vaccine revenues. The company aims to transform into a multiproduct company by 2030, focusing on oncology and infectious diseases.

BioNTech advances oncology pipeline, eyes growth amid financial challenges

BioNTech is making significant strides in its oncology pipeline, aiming for multiple product launches by 2026 and focusing on cancer vaccines and mRNA treatments.
While facing financial losses and short-term profitability challenges, the company remains optimistic about its growth trajectory and revenue potential.
Strategic investments in technology platforms, commercial readiness, and partnerships position BioNTech for sustainable growth and value enhancement.
Balancing cost control, revenue generation, and clinical execution will be crucial for BioNTech to capitalize on opportunities and navigate challenges effectively.

BioNTech reports Q2 progress in oncology pipeline amid financial challenges

BioNTech's Q2 2024 earnings call highlighted progress in oncology and COVID-19 vaccines, with total revenues of EUR 129 million but a net loss of EUR 808 million. The company remains focused on advancing innovative therapies and expanding its global manufacturing capabilities.

BioNTech reports robust Q3 earnings, focuses on oncology pipeline

BioNTech's Q3 2024 performance was strong, driven by COVID-19 vaccines and oncology trials.
While facing revenue challenges in certain regions, the company remains focused on growth.
Opportunities lie in advancing oncology pipeline and demonstrating product potential.
Maintaining a strong cash position provides flexibility for future investments.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

BioNTech SE operates as immunotherapy company, which engages therapies for cancer and other serious diseases. Its product pipeline include BNT162b2, BNT161, BNT164, FixVac, iNeST, RiboMabs, CAR-T Cells, TCRs and Next-Gen CP Immunomodulators. The company was founded by Christopher Huber, Oezlem Tuereci, and Ugur Sahin on June 2, 2008 and is headquartered in Mainz, Germany.

Pfizer

Extra doses contained in the vials of Pfizer Inc's (NYSE: PFE) COVID-19 vaccine do not need to be discarded, according to the United States Food and Drug Administration, Reuters reported Wednesday.  What Happened: Labeling confusion had led to hospital pharmacists discarding one in every six doses of the vaccine made jointly by Pfizer and its German partner BioNTech SE (NASDAQ: BNTX), Stat News had reported earlier.

Pfizer COVID-19 Vaccine US Supply Could Rise 40% As FDA Clears Use Of Extra Doses In Vials

Hospital pharmacists in the US have been throwing out extra COVID-19 vaccine doses as the country battles with record numbers of infections and deaths.

Pfizer vaccine doses thrown away in US after labelling confusion

But some doses may have already been thrown away.

Report: Pfizer Vaccine Vials Hold Extra Doses—Increasing U.S. Supply By Up To 40%

Doses of Pfizer's vaccine were quarantined in California and Alabama after an “anomaly” in the transportation process caused the storage temperature to get too cold.

U.S. quarantines Pfizer vaccine shipments in California and Alabama after transit 'anomaly' left vials too cold

Moderna

The Moderna and Pfizer vaccines have one key similarity.

What Pfizer's Vaccine Authorization Means for Moderna

MAINZ, GERMANY, and SHANGHAI, CHINA, December 16, 2020 (GLOBE NEWSWIRE) — BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) and Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (“Fosun Pharma” or “Group”; Stock Code: 600196.SH, 02196.HK) today announced an agreement to supply Mainland China with an initial 100 million doses of their BNT162 mRNA-based vaccine candidate against COVID-19 in 2021, subject to regulatory approval. Initial supply will be delivered from BioNTech's production facilities in Germany. 

BioNTech and Fosun Pharma to Supply China with mRNA-based COVID-19 Vaccine

Millions of doses of Pfizer Inc (NYSE: PFE) and BioNTech SE's  (NASDAQ: BNTX) COVID-19 vaccine will be administered in China alongside home-made options, Bloomberg reported Tuesday. What Happened: Local pharmaceutical firm Shanghai Fosun Pharmaceutical (Group) Co, Ltd (OTC: SFOSF) —  which signed an agreement with BioNTech in March — will pay the German company $300 million (EUR 250 million) for an initial 50 million doses, according to Bloomberg.

China Secures 100M Doses Of Pfizer-BioNTech COVID-19 Vaccine For 2021

Amplify Travel Tech ETF

VanEck Vectors Gaming ETF

First Trust NASDAQ Global Auto Index Fund

US Global Jets ETF

iShares MSCI Global Metals & Mining Producers ETF

The United States has geared up for the largest-ever immunization with the rollout of the COVID-19 vaccine.

Sector ETFs to Gain the Most on COVID-19 Vaccine Rollout

Mesoblast

Anavex Life Sciences

Eli Lilly

vTv Therapeutics

Eli Lilly (NYSE: LLY) shares are trading higher on Tuesday after the company announced it will acquire Prevail for total consideration of $26.50 per share in cash. The company also issued the fiscal year 2020 EPS and sales guidance above analyst estimates.

Why Mesoblast, Anavex And More Pharma Stocks Are Moving Today

BioNTech S.E. (NASDAQ: BNTX) was in the spotlight on Tuesday after it received a sizable price target hike from one key analyst.

Why One Analyst Sees Big Upside in This COVID-19 Vaccine Stock

A World Health Organization senior official said on Tuesday that the agency was in talks with Pfizer to include its COVID-19 vaccine as part of an early global roll out.

WHO sees "strong commitment" from Pfizer on affordable COVID vaccine

Celldex Therapeutics

Co-Diagnostics

Cardiff Oncology

Seres Therapeutics

Nestle SA

Novavax

Trillium Therapeutics

Vaxart

The highest performers of the year are biotechs fighting COVID-19 and cancer. Are they still buys for 2021?

These Were the 10 Best Healthcare Stocks of 2020

To reward shareholders, the company is employing a common technology strategy.

Could BioNTech Be a Millionaire-Maker Stock?

Which Is the Best COVID Vaccine Stock Now: Pfizer, BioNTech, or Moderna?

CRISPR Therapeutics

Denali Therapeutics

Mirati Therapeutics

Seagen

Zai Lab Ltd.

It's a relief to know Covid-19 vaccines are on the way. But there are plenty of other great biotechs that have been overlooked in the market frenzy.

7 Biotech Stocks To Buy Beyond Covid Vaccine Plays

"There is not one part of this country that's not being touched today through Wednesday," Gen. Gustave Perna, who's in charge of logistics for Operation Warp Speed, said.

U.S. administers first shots of Pfizer's Covid vaccine, launching a historic rollout

With more than 180K daily reported cases as of yesterday, with more than 109K hospitalizations and nearly 1500 deaths on Sunday alone, this vaccine availability is not just historic, it's momentous.

Historic Day for Pfizer (PFE), Covid-19 Vaccine

Pfizer is in talks to supply the US government with another 100 million doses of the company's coronavirus vaccine, CEO Albert Bourla said Monday. That would add to the 100 million doses Pfizer plans to deliver by the end of March under an order the Trump administration placed in July, Bourla told CNN.

Pfizer in talks to supply US with another 100 million vaccine doses

"This is a vaccine that was developed without cutting corners from a company with 171 years of credentials," Pfizer CEO Albert Bourla said.

Pfizer's CEO hasn't gotten his Covid vaccine yet, saying he doesn't want to cut in line

Pfizer and the U.S. are working out details on timing, CEO Albert Bourla told CNBC's "Squawk Box" in an interview.

Pfizer negotiating with U.S. to provide an additional 100 million Covid vaccine doses, CEO says

"This has been a challenging process because there have been multiple conversations happening as recently as November," Dr. Scott Gottlieb told CNBC.

U.S. could have bought additional Pfizer vaccines in November but passed, says Pfizer board member

FDA grants emergency use approval to Pfizer (PFE)/BioNTech's (BNTX) COVID-19 vaccine candidate.

COVID-19 Vaccine Race Heats Up as Pfizer Gets Emergency Nod

Pfizer CEO Albert Bourla on Monday said the company has not signed an agreement yet with the United States on providing 100 million more coronavirus vaccine doses in 2021, telling CNN it is still negotiating whether to deliver the drug in the second or third quarter of the year.

Pfizer CEO says still negotiating with U.S. on more coronavirus vaccines

Pfizer Inc. and its Germany-based partner BioNTech SE said overall results of a Phase 1/2 study in Germany of its COVID-19 vaccine candidate, BNT162b2, mirrored those from the U.S. study. The companies said the results supported "the favorable safety profile and robust induction of virus-specific antibody responses.

Pfizer, BioNTech COVID-19 vaccine candidate study in Germany support safety profile

NEW YORK and MAINZ, GERMANY, December 14, 2020 — Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced additional data on neutralizing antibody and T cell responses from the Phase 1/2 trial with BNT162b2 conducted in Germany. The study results demonstrate that BNT162b2 elicits a combined adaptive humoral and cellular immune response against SARS-CoV-2 and provide insights into the composite nature of BNT162b2-induced T cell immunity. The results were published on the preprint server MedRxiv and are available here . BNT162b2 is an investigational COVID-19 vaccine developed by Pfizer-BioNTech. It has been authorized for emergency use for individuals 16 years of age and older in several countries around the world.

Pfizer and BioNTech Provide Data from German Phase 1/2 Study Further Characterizing Immune Response Following Immunization with Lead COVID-19 Vaccine Candidate BNT162b2

News for BioNTech SE Stock (BNTX)